OncoSec Medical is a late-stage immuno-oncology company focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Co.'s main technology, ImmunoPulse®, is a drug-device therapeutic modality platform comprised of OncoSec Medical System EP device (the OMS EP Device) and a DNA plasmid delivery and application method. The OMS EP Device can be adapted to treat various tumor types, and consists of an electrical pulse generator and disposable applicator. Co.'s main product candidate is a plasmid encoding interleukin-12 called tavokinogene telseplasmid. The ONCS stock yearly return is shown above.
The yearly return on the ONCS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONCS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|